Contrary to results from clinical trials, a population-based study found worse disease-free survival among patients who experience adjuvant hormone therapy–related hot flashes.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS.